Sandy Spring Bank Neu Base Therapeutics, Inc. Transaction History

Sandy Spring Bank

  • $2.18 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 09, 2020
SELL
$7.25 - $9.71 $3,625 - $4,855
-500 Closed
0 $0
Q3 2019

Nov 01, 2019
BUY
$3.15 - $6.59 $1,575 - $3,295
500 New
500 $2,000

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Sandy Spring Bank Portfolio

Follow Sandy Spring Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sandy Spring Bank, based on Form 13F filings with the SEC.

News

Stay updated on Sandy Spring Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email